Cargando…
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756077/ https://www.ncbi.nlm.nih.gov/pubmed/30631117 http://dx.doi.org/10.1038/s41375-018-0320-9 |
| _version_ | 1783453345314242560 |
|---|---|
| author | Dodero, A. Guidetti, A. Tucci, A. Barretta, F. Novo, M. Devizzi, L. Re, A. Passi, A. Pellegrinelli, A. Pruneri, G. Miceli, R. Testi, A. Pennisi, M. Di Chio, M. C. Matteucci, P. Carniti, C. Facchetti, F. Rossi, G. Corradini, P. |
| author_facet | Dodero, A. Guidetti, A. Tucci, A. Barretta, F. Novo, M. Devizzi, L. Re, A. Passi, A. Pellegrinelli, A. Pruneri, G. Miceli, R. Testi, A. Pennisi, M. Di Chio, M. C. Matteucci, P. Carniti, C. Facchetti, F. Rossi, G. Corradini, P. |
| author_sort | Dodero, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6756077 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67560772019-09-24 Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma Dodero, A. Guidetti, A. Tucci, A. Barretta, F. Novo, M. Devizzi, L. Re, A. Passi, A. Pellegrinelli, A. Pruneri, G. Miceli, R. Testi, A. Pennisi, M. Di Chio, M. C. Matteucci, P. Carniti, C. Facchetti, F. Rossi, G. Corradini, P. Leukemia Letter Nature Publishing Group UK 2019-01-10 2019 /pmc/articles/PMC6756077/ /pubmed/30631117 http://dx.doi.org/10.1038/s41375-018-0320-9 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter Dodero, A. Guidetti, A. Tucci, A. Barretta, F. Novo, M. Devizzi, L. Re, A. Passi, A. Pellegrinelli, A. Pruneri, G. Miceli, R. Testi, A. Pennisi, M. Di Chio, M. C. Matteucci, P. Carniti, C. Facchetti, F. Rossi, G. Corradini, P. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma |
| title | Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma |
| title_full | Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma |
| title_fullStr | Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma |
| title_full_unstemmed | Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma |
| title_short | Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma |
| title_sort | dose-adjusted epoch plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large b-cell lymphoma |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756077/ https://www.ncbi.nlm.nih.gov/pubmed/30631117 http://dx.doi.org/10.1038/s41375-018-0320-9 |
| work_keys_str_mv | AT doderoa doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT guidettia doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT tuccia doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT barrettaf doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT novom doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT devizzil doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT rea doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT passia doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT pellegrinellia doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT prunerig doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT micelir doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT testia doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT pennisim doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT dichiomc doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT matteuccip doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT carnitic doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT facchettif doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT rossig doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma AT corradinip doseadjustedepochplusrituximabimprovestheclinicaloutcomeofyoungpatientsaffectedbydoubleexpressordiffuselargebcelllymphoma |